Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosamprenavir→

Fosamprenavir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
226700-79-4
PubChem CID
131536
Molecular formula
C25H36N3O9PS
Molecular weight
585.6 g/mol
Drug class
HIV-1 protease inhibitor prodrugantiretroviral agent
Mechanism of action
Fosamprenavir is a phosphate prodrug that is hydrolysed to amprenavir. Amprenavir inhibits HIV-1 protease, preventing cleavage of viral gag-pol polyproteins and production of mature infectious virions.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and eligible paediatric patients; current use depends on resistance profile, drug interactions and national treatment guidelines

Sources: US DailyMed — LEXIVA (fosamprenavir) · NLM MeSH — Fosamprenavir · FDA product information

Identification source: PubChem record (CID 131536). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fosamprenavir Environmental Risk Assessment (ERA) (the Fosamprenavir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.